Literature DB >> 21906648

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Christopher B Fox1, Susan L Baldwin, Malcolm S Duthie, Steven G Reed, Thomas S Vedvick.   

Abstract

Squalene-based oil-in-water emulsions have been used for years in some seasonal and pandemic influenza vaccines. However, concerns have been expressed regarding squalene source and potential biological activities. Little information is available regarding the immunomodulatory activity of squalene in comparison with other metabolizable oils in the context of oil-in-water emulsions formulated with vaccines. The present work describes the manufacture and physical characterization of emulsions composed of different classes of oils, including squalene, long chain triglycerides, a medium chain triglyceride, and a perfluorocarbon, all emulsified with egg phosphatidylcholine. Some differences were apparent among the non-squalene oils in terms of emulsion stability, including higher size polydispersity in the perfluorocarbon emulsion, more rapid visual instability at 60°C for the long-chain triglyceride and perfluorocarbon emulsions, and an increased creaming rate in the medium-chain triglyceride emulsion at 60°C as detected by laser scattering optical profiling. The biological activity of each of these emulsions was compared when formulated with either a recombinant malaria antigen or a split-virus inactivated influenza vaccine. Overall, vaccines containing the squalene emulsion elicited higher antibody titers and more abundant long-lived plasma cells than vaccines containing emulsions based on other oils. Since squalene-based emulsions show higher adjuvant potency compared to the other oils tested, non-squalene oils may be more suitable as carriers of amphiphilic or hydrophobic immunostimulatory molecules (such as TLR agonists) rather than as stand-alone adjuvants.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906648      PMCID: PMC3224191          DOI: 10.1016/j.vaccine.2011.08.089

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acylmuramyldipeptide and synthetic low toxicity analogues of lipid A.

Authors:  M Tsujimoto; S Kotani; T Okunaga; T Kubo; H Takada; T Kubo; T Shiba; S Kusumoto; T Takahashi; Y Goto
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

Review 2.  Critical appraisal of emulsified oil adjuvants applied to viral vaccines.

Authors:  M R Hilleman
Journal:  Prog Med Virol       Date:  1966

3.  A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems.

Authors:  T K Bock; B W Müller
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

4.  The role of surface in the biological activities of trehalose 6,6'-dimycolate. Surface properties and development of a model system.

Authors:  G S Retzinger; S C Meredith; K Takayama; R L Hunter; F J Kézdy
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

5.  Vitamin E adjuvant formulations in mice.

Authors:  R P Tengerdy; N G Lacetera
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

6.  Humoral responses following immunization with Leishmania infantum (ex. Oklahoma): a comparison of adjuvant efficacy in the antibody responses of Balb-C mice.

Authors:  R M Lasarow; D L Williams; J H Theis
Journal:  Int J Immunopharmacol       Date:  1992-07

7.  Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants.

Authors:  L F Woodard; R L Jasman
Journal:  Vaccine       Date:  1985-06       Impact factor: 3.641

8.  Factors influencing protection against experimental tuberculosis in mice by heat-stable cell wall vaccines.

Authors:  E Ribi; R L Anacker; W Brehmer; G Goode; C L Larson; R H List; K C Milner; W C Wicht
Journal:  J Bacteriol       Date:  1966-10       Impact factor: 3.490

9.  Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

10.  Adjuvant activity of a novel metabolizable lipid emulsion with inactivated viral vaccines.

Authors:  J A Reynolds; D G Harrington; C L Crabbs; C J Peters; N R Di Luzio
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

View more
  17 in total

Review 1.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

Review 2.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

Review 3.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

4.  IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Authors:  Anthony L Desbien; Natasha Dubois Cauwelaert; Steven J Reed; Hilton R Bailor; Hong Liang; Darrick Carter; Malcolm S Duthie; Christopher B Fox; Steven G Reed; Mark T Orr
Journal:  J Immunol       Date:  2016-10-28       Impact factor: 5.422

5.  Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Authors:  Christopher B Fox; Susan L Baldwin; Thomas S Vedvick; Evelina Angov; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

6.  Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  AAPS PharmSciTech       Date:  2012-03-14       Impact factor: 3.246

7.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

8.  Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.

Authors:  Emilie Seydoux; Hong Liang; Natasha Dubois Cauwelaert; Michelle Archer; Nicholas D Rintala; Ryan Kramer; Darrick Carter; Christopher B Fox; Mark T Orr
Journal:  J Immunol       Date:  2018-05-16       Impact factor: 5.422

9.  A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.

Authors:  Million A Tegenge; Robert J Mitkus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-04       Impact factor: 2.745

10.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.